Counterattacking drug-resistant tuberculosis: Molecular strategies and future directions

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 9, 2012, Pages 959-961

  Nguyen, Liem ^a   Jacobs, Michael R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CLAVULANIC ACID; DAPSONE; ETHIONAMIDE; FOLIC ACID ANTAGONIST; MEROPENEM; SULFAMETHOXAZOLE; SULFONAMIDE; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BIOFILM; DRUG POTENTIATION; DRUG RESISTANT TUBERCULOSIS; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERANCE; HOST RESISTANCE; HUMAN; MOLECULAR MECHANICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TRANSCRIPTION REGULATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; VIRULENCE FACTORS;

EID: 84868132349     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.97     Document Type: Review

References (19)

1. Udwadia ZF. MDR, XDR, TDR tuberculosis: ominous progression. Thorax 67(4), 286-288 (2012).
2. Wright GD. Resisting resistance: new chemical strategies for battling superbugs. Chem. Biol. 7(6), R127YR132 (2000).
3. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS. Meropenemclavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323(5918), 1215-1218 (2009).
4. Kurz S, Bonomo RA. Reappraising the use of b-lactams to treat tuberculosis. Expert Rev. Anti Infect. Ther. 10(9), 999-1006 (2012).
5. Wolff KA, Nguyen L. Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis. Expert Rev. Anti Infect. Ther. 10(9), 971-981 (2012).
6. Weber W, Schoenmakers R, Keller B et al. A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc. Natl Acad. Sci. USA 105(29), 9994-9998 (2008).
7. Willand N, Dirié B, Carette X et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15(5), 537-544 (2009).
8. Huang TS, Kunin CM, Yan BS, Chen YS, Lee SS, Syu W Jr. Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J. Antimicrob. Chemother. 67(3), 633-637 (2012).
9. Ong W, Sievers A, Leslie DE. Mycobacterium tuberculosis and sulfamethoxazole susceptibility. Antimicrob. Agents Chemother. 54(6), 2748; author reply 2748-2749 (2010).
10. Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, Roberts GD. Tuberculosis and trimethoprimsulfamethoxazole. Antimicrob. Agents Chemother. 53(11), 4789-4793 (2009).
11. Barr J. A short history of dapsone, or an alternative model of drug development. J. Hist. Med. Allied Sci. 66(4), 425-467 (2011).
12. Favrot L, Ronning DR. Targeting the mycobacterial envelope for tuberculosis drug development. Expert Rev. Anti Infect. Ther. 10(9), 1023-1036 (2012).
13. Adams KN, Takaki K, Connolly LE et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145(1), 39-53 (2011).
14. Viveiros M, Martins M, Rodrigues L et al. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev. Anti Infect. Ther. 10(9), 983-998 (2012).
15. D'Costa VM, King CE, Kalan L et al. Antibiotic resistance is ancient. Nature 477(7365), 457-461 (2011).
16. Liu J, Gordon B. Targeting the global regulator Lsr2 as a novel approach for antituberculosis drug development. Expert Rev. Anti Infect. Ther. 10(9), 1049-1053 (2012).
17. Burian J, Ramón-García S, Howes CG, Thompson CJ. WhiB7, a transcriptional activator that coordinates physiology with intrinsic drug resistance in Mycobacterium tuberculosis. Expert Rev. Anti Infect. Ther. 10(9), 1037-1047 (2012).
18. Jayachandran R, Scherr N, Pieters J. Elimination of intracellularly residing Mycobacterium tuberculosis through targeting of host and bacterial signaling mechanisms. Expert Rev. Anti Infect. Ther. 10(9), 1007-1022 (2012).
19. Islam MS, Richards JP, Ojha AK. Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms. Expert Rev. Anti Infect. Ther. 10(9), 1055-1066 (2012).